Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children
- PMID: 16816558
- DOI: 10.1097/01.aids.0000232237.20792.68
Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children
Abstract
Objectives: To describe the relationship between absolute CD4 cell count and the short-term risk of disease progression in HIV-1-infected children.
Design: A meta-analysis of individual longitudinal data on HIV-1-infected children enrolled in trials and cohort studies in Europe and the USA.
Methods: The risks of progression to death and AIDS (or death) within 12 months, in terms of age and the most recent CD4 cell count, were estimated using parametric survival models. The analysis was restricted to measurements before the start of antiretroviral therapy except zidovudine monotherapy. The values of the absolute CD4 cell count and percentage predicting selected levels of disease progression risk were determined from this and previous models.
Results: A total of 566 deaths was observed over 9128 person-years of follow-up, and 992 children progressed to AIDS or death over 7309 person-years of follow-up. In children older than 4 or 5 years, the estimated risk of disease progression increased sharply when the CD4 cell count fell below 200-300 cells/microl. As with other immunological markers, CD4 cell count was less prognostic in younger children. The CD4 cell count values predicting a 12-month risk of death of 2-5% and of AIDS of 5-10% were much more strongly influenced by age than equivalent CD4 cell percentage values.
Conclusion: This study suggests it may be appropriate to extend CD4 cell count criteria for initiating antiretroviral therapy in HIV-1-infected adults to children as young as 4 or 5 years. Monitoring by CD4 cell count in younger children is problematical because age is a highly influential variable.
Similar articles
-
Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data.Lancet. 2005 Nov 26;366(9500):1868-74. doi: 10.1016/S0140-6736(05)67757-4. Lancet. 2005. PMID: 16310553
-
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children.AIDS. 2010 May 15;24(8):1213-7. doi: 10.1097/QAD.0b013e3283389f41. AIDS. 2010. PMID: 20386428
-
Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis.Lancet. 2003 Nov 15;362(9396):1605-11. doi: 10.1016/s0140-6736(03)14793-9. Lancet. 2003. PMID: 14630440
-
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.Lancet. 2009 Apr 18;373(9672):1352-63. doi: 10.1016/S0140-6736(09)60612-7. Epub 2009 Apr 8. Lancet. 2009. PMID: 19361855 Free PMC article. Review.
-
Clinical and biological disease progression in vertically acquired paediatric HIV infection.Med Wieku Rozwoj. 2003 Oct-Dec;7(4 Pt 1):437-48. Med Wieku Rozwoj. 2003. PMID: 15010554 Review.
Cited by
-
Advances in Pediatric Pharmacology, Therapeutics, and Toxicology.Adv Pediatr. 2016 Aug;63(1):227-54. doi: 10.1016/j.yapd.2016.04.015. Adv Pediatr. 2016. PMID: 27426903 Free PMC article. Review.
-
CD4 cell count criteria to determine when to initiate antiretroviral therapy in human immunodeficiency virus-infected children.Pediatr Infect Dis J. 2010 Oct;29(10):966-8. doi: 10.1097/INF.0b013e3181e0554c. Pediatr Infect Dis J. 2010. PMID: 20418798 Free PMC article.
-
Absolute CD4+ T-lymphocyte count as a surrogate marker of pediatric human immunodeficiency virus disease progression.Pediatr Infect Dis J. 2008 Jul;27(7):629-35. doi: 10.1097/INF.0b013e3181693892. Pediatr Infect Dis J. 2008. PMID: 18520446 Free PMC article.
-
Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper.Br J Clin Pharmacol. 2022 Dec;88(12):4965-4984. doi: 10.1111/bcp.14958. Epub 2021 Jul 23. Br J Clin Pharmacol. 2022. PMID: 34180088 Free PMC article. Review.
-
When to start, what to start and other treatment controversies in pediatric HIV infection.Paediatr Drugs. 2012 Dec 1;14(6):361-76. doi: 10.2165/11599640-000000000-00000. Paediatr Drugs. 2012. PMID: 23013459
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials